483
Cilag AGFDA 483 - Cilag AG - July 16, 2019
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Cilag AG, a drug manufacturer in Schaffhausen, Switzerland, revealed four observations related to quality system deficiencies. These included issues with equipment maintenance, failure to follow established microbiological test procedures, and incomplete laboratory records for instrument calibration and endotoxin testing traceability. The findings indicate a need for improved adherence to good manufacturing practices and documentation standards.
Open in Dashboard
ID · 24f39902-f5af-47ce-b648-514441b550a8